A six-month-long duration of TB treatment under the DOTS programme is fraught with issues like non-compliance by patients, mix up of drugs, etc., contributing to the emergence of multi-drug-resistant TB. Shortening the duration of treatment has been a priority area in the TB drug discovery research efforts. In a recent Phase 3 clinical trial (Study 31/A5349), a 4-month regimen is as efficacious as the 6-month regimen for treatment of drug-susceptible tuberculosis in patients. This landmark breakthrough is expected to strengthen the global efforts for the elimination of TB by 2030.
Ground Breaking Advancements in TB Treatment Regimen by Shingar and Pawan Sharma
